<DOC>
	<DOC>NCT00890084</DOC>
	<brief_summary>To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk</brief_summary>
	<brief_title>Telmisartan Tab Hypertension</brief_title>
	<detailed_description>Study Design:</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
	<criteria>Inclusion criteria: Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12.5 mg or 25 mg, in the usual way and in line with the SmPC and reimbursement criteria Exclusion criteria: Contraindications as in the Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>